SS-31 10mg research vial

SS-31 | Peptide Vials

10mg
$59.00
Regular price  $88.50 Sale price  $59.00
Skip to product information
SS-31 10mg research vial

SS-31 | Peptide Vials

$59.00
Regular price  $88.50 Sale price  $59.00
Strength

Bundle & save

Price $59.00

For research use only. Not for human consumption. Compassionate curators of fine peptides.

SS-31

Mollecule SS-31 is manufactured for researchers seeking premium-quality peptide materials supported by verified laboratory testing. Every production lot is independently tested by accredited third-party laboratories, with Certificates of Analysis (COAs) available to confirm purity, identity, and manufacturing consistency.

Pack
10mg Peptide Vials: $59.00
50mg Peptide Vials: $207.00

Related peptides

Sources & References

Peer-reviewed research

  • NEW ENGLAND JOURNAL OF MEDICINE

    Triple-Hormone-Receptor Agonist GLP-3 (RT) for Obesity - A Phase 2 Trial

    2023 DOI: 10.1056/NEJMoa2301972 Jastreboff AM, et al.

    View Source
  • THE LANCET

    GLP-3 (RT) for People with Type 2 Diabetes - A Phase 2 Trial

    2023 Rosenstock J, et al.

    View Source
  • NATURE MEDICINE

    GLP-3 (RT) for Metabolic Dysfunction-Associated Steatotic Liver Disease

    2024 Sanyal AJ, et al.

    View Source
  • LANCET DIABETES & ENDOCRINOLOGY

    Effects of GLP-3 (RT) on Body Composition

    2025 Coskun T, et al.

    View Source
  • PUBMED CENTRAL

    Triple Agonism Based Therapies for Obesity

    2025

    View Source
  • PUBMED CENTRAL

    GLP-3 (RT) - A Game Changer in Obesity Pharmacotherapy

    2025

    View Source
  • PUBMED CENTRAL

    Efficacy and Safety of GLP-3 (RT) - Systematic Review & Meta-Analysis

    2024

    View Source
  • ELI LILLY

    TRIUMPH-4 Phase 3 Trial Results

    2025

    View Source
  • NATURE CELL DISCOVERY

    Structural Analysis of Incretin Receptor Agonists

    2024

    View Source
  • PUBCHEM DATABASE

    GLP-3 (RT) Compound Information

    View Source
  • CLINICALTRIALS.GOV

    GLP-3 (RT) Clinical Trials Registry

    View Source